Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial
Completed · Phase 4 · NCT04708145
Conditions: Diabetic Retinopathy
At a glance
- Research payments reported, 2025
- $2.0M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 41
About the trial
- Sponsor
- Greater Houston Retina Research (with Regeneron Pharmaceuticals, Clinical Trials Resource Group, LLC)
- Tested
- Aflibercept Injection (drug)
- Dates
- Started 2021-06-01; completion 2024-07-31
- Results posted
- Not yet
The VOYAGE trial will assess diabetic retinopathy severity scale (DRSS) levels, through 112 weeks, while being managed with aflibercept as needed, among subjects who completed the 2-year PANORAMA trial (VGFTe-OD-1411) and were treated in a clinical setting prior to joining the VOYAGE study.
From ClinicalTrials.gov, last updated 2025-01-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $2.0M in research payments for this study in 2025 (37 payments).
Products named: Eylea
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Clinical Trials Resource Group LLC $2.0M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.